Literature DB >> 12604885

Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders.

Roland G Nador1, Amy Chadburn, Girija Gundappa, Ethel Cesarman, Jonathan W Said, Daniel M Knowles.   

Abstract

The majority of AIDS-related non-Hodgkin's lymphomas are clinically aggressive monoclonal B-cell Burkitt's lymphomas, large cell lymphomas, or immunoblastic lymphomas. In contrast, the lymphoid proliferations arising in solid organ transplant recipients, collectively referred to as posttransplantation lymphoproliferative disorders (PT-LPDs), represent a clinically and histopathologically heterogeneous group of Epstein-Barr virus (EBV)-driven B-cell proliferations of variable clonal composition. During a retrospective histopathologic review of lymphoid proliferations associated with human immunodeficiency virus (HIV) infection we identified 10 cases that morphologically resemble the polymorphic PT-LPDs. They arose in lymph nodes (five), lungs (two), and the parotid gland, perineum, and skin (one each). They exhibit a diffuse growth pattern and are composed of a polymorphic lymphoid cell population exhibiting a variable degree of plasmacytic differentiation, cytologic atypia, and numbers of atypical immunoblasts. A clonal B-cell population was detected by immunoglobulin heavy and light chain gene rearrangement and/or EBV terminal repeat analysis in 8 of the 10 (80%) cases by Southern blotting. The nongermline hybridizing bands were usually faint, however, suggesting that the clonal B-cell population represented only a subpopulation within the polymorphic lesion. Strong clonal rearrangement bands were present in one case in which there was clear morphologic evidence of transformation to diffuse large cell lymphoma. This case exhibited C-MYC, BCL-6, and p53 gene mutations. One other case exhibited a p53 gene mutation. The remaining eight cases lacked C-MYC, BCL-6, RAS, and p53 gene alterations. Clonal EBV infection was detected in 4 of the 10 (40%) lesions. Like EBV-containing PT-LPDs, all four EBV-positive HIV-associated polymorphic lesions were associated with type A EBV. The Kaposi's sarcoma-associated herpesvirus was detectable in two cases by polymerase chain reaction analysis, but not by Southern blotting. In situ hybridization demonstrated Kaposi's sarcoma-associated herpesvirus in some of the cytologically malignant-appearing cells. In conclusion, polymorphic B-cell lymphoproliferative disorders comparable morphologically and molecularly to those arising after solid organ transplantation also occur in association with HIV infection. As in the case of their polymorphic PT-LPD counterparts, their malignant status, biologic significance, and relationship to monomorphic B-cell lymphomas remain to be elucidated.

Entities:  

Mesh:

Year:  2003        PMID: 12604885     DOI: 10.1097/00000478-200303000-00002

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics.

Authors:  Yorick Sandberg; Ellen J van Gastel-Mol; Brenda Verhaaf; King H Lam; Jacques J M van Dongen; Anton W Langerak
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

2.  Nodular pattern of bone marrow infiltration: frequent finding in immunosuppression-related EBV-associated large B-cell lymphomas.

Authors:  Deborah W Sevilla; Erin M Weeden; Suzy Alexander; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  Virchows Arch       Date:  2009-10-06       Impact factor: 4.064

3.  A case of HIV-associated lymphoproliferative disease that was successfully treated with highly active antiretroviral therapy.

Authors:  Haruyuki Fujita; Momoko Nishikori; Akifumi Takaori-Kondo; Noriyoshi Yoshinaga; Yoshiaki Ohara; Takayuki Ishikawa; Hironori Haga; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2010-03-10       Impact factor: 2.490

4.  Polymorphic lymphoid proliferations occurring in HIV-positive patients: report of a case responding to HAART.

Authors:  Jenny Buxton; Clifford Leen; John R Goodlad
Journal:  Virchows Arch       Date:  2012-06-17       Impact factor: 4.064

Review 5.  HIV infection and lymphoma.

Authors:  K L Grogg; R F Miller; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

Review 6.  Pathology of lymphoma in HIV.

Authors:  Ethel Cesarman
Journal:  Curr Opin Oncol       Date:  2013-09       Impact factor: 3.645

7.  Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.

Authors:  Martin Schlee; Tanja Krug; Olivier Gires; Reinhard Zeidler; Wolfgang Hammerschmidt; Reinhard Mailhammer; Gerhard Laux; Guido Sauer; Josip Lovric; Georg W Bornkamm
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Lymphoproliferative Lesions in the Setting of HIV Infection: A Five-Year Retrospective Case Series and Review.

Authors:  Etienne Mahe; Catherine Ross; Monalisa Sur
Journal:  Patholog Res Int       Date:  2011-03-30

Review 9.  Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.

Authors:  E Campo; A Chott; M C Kinney; L Leoncini; C J L M Meijer; C S Papadimitriou; M A Piris; H Stein; S H Swerdlow
Journal:  Histopathology       Date:  2006-04       Impact factor: 5.087

10.  Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.

Authors:  Laura Mediani; Federica Gibellini; Jessika Bertacchini; Chiara Frasson; Raffaella Bosco; Benedetta Accordi; Giuseppe Basso; Massimo Bonora; Maria Luisa Calabrò; Adriana Mattiolo; Gianluca Sgarbi; Alessandra Baracca; Paolo Pinton; Giovanni Riva; Enrico Rampazzo; Luca Petrizza; Luca Prodi; Daniela Milani; Mario Luppi; Leonardo Potenza; Anto De Pol; Lucio Cocco; Silvano Capitani; Sandra Marmiroli
Journal:  Oncotarget       Date:  2016-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.